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Summary
The present studies were undertaken to determine whether the interleukin 4 binding proteins
(IL4BPs) previously identified in the biological fluids of mice are soluble forms ofIL4Rs . We
also studied the binding properties ofIL4BPs in order to gain insight into their physiological
role in vivo . Affinity-purified IL4BPs and recombinant soluble IL4Rs generated similar one-
dimensional (Cleveland) peptide maps after digestion with either Staphylococcus aureus V8 protease
or trypsin, indicating structural similarities . Furthermore, a rat mAb directed against the murine
IL4Rs immunoprecipitated the IL4BPs and completely inhibited binding of 1251-IL4 to a
purified preparation of IL4BPs. Taken together these data indicate that the IL4BPs are soluble
IL4Rs. At 4°C the IL4BPs competitively inhibited the binding of IL-4 to membrane IL4Rs
but their ability to prevent binding of IL4 to cells at 37°C, at the same concentrations, was
significantly reduced. Kinetic binding studies of soluble IL4BPs vs . membrane IL4Rs disclosed
important differences in their rates of dissociation from IL-4 . Whereas dissociation at 4°C was
slow for both, dissociation of 114 from ILBPs at 37°C was considerably faster (t 1i2 of 2 min)
than dissociation of IL4 from membrane IL4Rs (t i/2 of -69 min) . Temperature-dependent
changes in dissociation kinetics were reversible, and could not be accounted for by either inactivation
of the IL4BPs at 37°C or receptor internalization . Additional experiments also demonstrated
that when IL4BPs bind to IL4 at 37°C, the IL4/IL4BPs complex can rapidly dissociate, allowing
IL-4 to bind to membrane IL4Rs . In addition, binding of 114 by the IL4BPs protects IIA from
proteolytic degradation . Taken together, these results suggest that the IL4BPs are naturally occurring
forms of soluble II,r4Rs and that some of their properties (fast dissociation kinetics and protection
of 1174 from proteolysis) are consistent with a potential role as carrier proteins for IL-4 in the
circulation .
A number of hormone and cytokine receptors exist in both
membrane-bound and soluble forms (e.g. insulin-like
growth factor and growth hormone receptors, as well as
receptors for IIr2, IL4,1176, andTNF [1-111) . Soluble cytokine
receptors usually represent truncated forms of the membrane-
bound molecules, lacking the transmembrane and intracyto-
plasmic domains but retaining the ligand-binding extracyto-
plasmic domain (5, 9, 10, 12, 13) . The roles played by soluble
cytokine receptors in vivo are unclear. Possible functions in-
clude : (a) inhibition of cytokine activity in biological fluids
(5, 9-11, 14, 15), thus confining the activity of cytokines to
their site of secretion; (b) signaling, by interacting with re-
ceptor-associated molecules on the membranes of target cells
(e.g ., IL6R) (16) ; and (c) transport ofcytokines in the circu-
lation, thus protecting their respective ligands from degra-
dation and/or secretion, or increasing their half life in the
circulation until they are delivered to target cells at distant
anatomical sites (17) .
Recently, we described the presence of IL-4 binding pro-
teins (IL4BPs) 1 in normal mouse serum and ascitic fluid
(15) . IL4BPs bind IL-4 with high affinity and inhibit the ac-
tivity of 114 in vitro (15) . Mosley, et al . (9) have described
cDNAs encoding both the full length IL-4R molecules and
secreted, truncated forms ofIL4Rs . COS-7 cells transfected
with cDNA clones encoding the latter, secreted a soluble form
of the IL4R that retained its ligand-binding capacity and,
inhibited both the binding and activity of IL4 .
The purpose of the present study was to determine whether
IL4BPs are related to soluble IL4Rs (slIr4R) and to then
investigate the binding properties ofsoluble IL4BPs in order
to gain insight into their potential functions in vivo as IL-
4-inhibitors or as IL-4-carrier proteins. Based on one-
dimensional peptide maps and reactivity with amAb directed
against the murine IL4Rs, the IL4BPs purified from ascitic
fluid are structurally and immunologically related to sIL4Rs
and thus are likely to be their naturally-occurring form . Ki-
1 Abbreviation used in this paper: 11 4BP, 11,4 binding protein .
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IIr4BPs indicate significant differences in their dissociation
kinetics at 37°C : dissociation ofIL4 from soluble IIr4BPs
is 30-40-fold faster than that from membrane IIr4Rs . In ad-
dition, kinetic and equilibrium dissociation constants (Kd)
suggest adecreased affinity of solubleIIr4BPs with increased
temperature (4°C vs. 37°C) . Accordingly, IIr4BPs compete
less effectively with membrane IIL4Rs for thebindingofIL4
at 37°C. In a two-step incubation experiment, 1251_114 that
was previously bound by IIr4BPs could dissociate and bind
to membrane IIr4Rs on HT-2 cells at 37°C but not at 4°C .
Finally, binding of IIr4 by the soluble IIr4BPs resulted in
acquisition of resistance of IIr4 to proteolytic degradation .
Taken together, these results suggest that solubleIIr4BPs may
play a role as carrier proteins for IIr4 in vivo.
Materials and Methods
Cells, Antibodies, andReagents.
￿
The11,2/114-responsiveT cell
line, HT-2 (18), was maintained in RPMI-1640 medium (Gibco
Laboratories, Grand Island, NY) supplemented with 10% heat-
inactivatedFCS(Hyclone Laboratories, Logan, UT), 100U/ml pen-
icillin, 100 ug/ml streptomycin, 10 jug/ml gentamicin, 2 mM
L-glutamine, 50wM 2-ME, 1mM sodium pyruvate,0.1 mM nones-
sential amino acids and 10 U/ml recombinant human 11,2 (IL2 ;
Amgen, Thousand Oaks, CA) as described (19) . The rat anti-mouse
114 antibody, 11BIl (20), was obtained by growingthe 11B11 hy-
bridoma in a VLS Cell Culture System (Amicon, Beverley, MA) .
The final concentrate contained>3 mg/ml of the 11B11 antibody
at >90% purity, as determined by a rat Ig-specificRIA andSDS-
PAGE, respectively. AratmAb directed against themurine IL4Rs
was purchased from Genzyme (Cambridge, MA) . This antibody
inhibits the binding of IL4 to both membrane and soluble IIr4Rs
(21) . Recombinant murine 11,4 was a generous gift from Dr. K.
Grabstein (Immunex Corp., Seattle, WA) and recombinant mu-
rine soluble IIAR (9, 22) was kindly provided by Dr. Maureen
Howard (DNAX, Palo Alto, CA) . Staphylococcus aureus strain V8
protease (type XVII), trypsin coupled to polyacrylamide beads and
hydroxyapatite (type I) were purchased from Sigma ChemicalCo .
(St . Louis, MO); Affigel-10 was obtained from BioRad (Richmond,
CA) .
Purification of IL4BPs.
￿
Murine ascitic fluidwas chosen as the
source of IIr4BPs . IIr4BPs are constitutively present in the biolog-
ical fluids of normal mice, including serum and urine, but their
concentration in ascitic fluid is twice that found in normal serum
(15) . In addition, larger volumes can be obtained . Previous esti-
mates basedon I14-binding activity and assumingan averagemol
wt of 40 kD, suggested an approximate concentration of IIABPs
in murine ascitic fluid of 50 ng/ml (1.25 x 10' M) . Ascites were,
therefore, induced with a spontaneous IgM-secreting myeloma
(MTSB) obtained from an elderly BALB/c mouse . These cells se-
crete IgMK . Myeloma cells were grown in the peritoneal cavity
of Pristane-primed BALB/c mice for the generation of ascites. Al-
though the myeloma cells might secrete soluble IL4BPs, thebulk
of the 11,01s in ascitic fluid probably comes from serum since
the concentration of IIr4BPs in serum is 50% as high as that in
ascites. IL4BPs were purified from pooled murine ascitic fluidby
affinity chromatography on an 11,4-Affigel-10 column followed by
removal of contaminating proteins by hydroxyapatite chromatog-
raphy. Briefly, 500ml ofpooled murine ascitic fluid, was centrifuged
and delipidated using 1,1,2-trichloro-trifluorethane (0.7 v/v) and
waspassed over an 11,4-Affigel-10column, previously prepared by
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coupling 50 Ftg ofrIL4 to 0.5 ml Affigel-10following the manufac-
turer's instructions. After extensive washing with ice-cold PBS,
the bound material was eluted with 6M deionized urea in 0.1M
Tris-HCl buffer, pH 8.0 . The eluates were pooled, concentrated
and equilibrated against 7.5mM phosphate buffer, pH 7.2 using
Amicon Centricon-10 devices(MW cut-off of 10 kD). The con-
centratedIIABPs preparations were further purified by incubation
with hydroxyapatite equilibrated in 7.5 mM phosphate buffer,pH
7.2 . Greater than 90% of the IL4 binding activity remained in
the supernatant while most of the contaminating proteins were
removed . This method resulted in a >105-fold increase in specific
activity (binding activity/protein) over that of the starting mate-
rial . As previously reported using a different purification protocol
(15), allofthe renatured IIr4-binding activity recovered after SDS-
PAGE was associated with molecules in the range of 30-40 kD.
Iodination ofrIL4, RecombinantSoluble IL4R andIL4BPs.
￿
rIL4
was iodinated using Iodogen (Pierce Chemicals, Rockford, IL)-
coated tubes and repurified over an 11B11-Sepharose column, as
described by Lowenthal, et al . (23) . The concentration of the la-
beled 1Ir4 preparation wasdetermined based on its biologic activity
in theHT-2 proliferation assay (24) andcomparison with an unla-
beled rIIr4 standard . The final 1211-IIA preparation had a specific
activity of 2 x 106 cpm/pmol . Recombinant soluble IIr4Rs or
purified IL4BPs were iodinated using the lodogenmethod andwere
then centrifuged through Sephadex G-25 minicolumns in order
to remove free iodine . For the one-dimensional peptide maps, the
iodinated IIABPs preparation was further purified by preparative
SDS-PAGE and elution of the 30-40 kD band .
One-Dimensional Aptide (Cleveland) Maps.
￿
One-dimensional pep-
tide maps of iodinated soluble rIIAR and purified IL4BPs were
carried out following the procedure described by Cleveland, et al .
(25) . Briefly, aliquots of iodinated, soluble r1Ir4Rs or IIABPs (2-5
x 101 cpm) in 45 ld of PBS-0.2% SDS containing 0.5 mg/ml
BSA as carrier protein, were incubated for 15 min at 37°C in the
presence or absence of staphylococcal V8 protease (3 I~g) or im-
mobilized trypsin (1 ug). Reactions were stoppedby the addition
of 50 Al of 2x Laemmli sample buffer (26) containing 5% 2-ME
and boiling for 3min. Samples were then subjected to SDS-PAGE
on 15%polyacrylamide gels followed by exposure to KodakXAR2
films (Kodak, Rochester, NY) for 2-5 d at -70°C .
Measurement of ' 251-IL4 Binding to Cells and to Soluble IL4BPs.
Binding of '251-IL4 to HT-2 cells was measured after incubation
at 4°C and centrifugation through a dibutyl/dioctyl phthalate oil
mixture, as described (24) . HT-2 cells possess a single class ofhigh
affinity 11,4-binding sites with a dissociation constant (Kd) of 5 x
10-11 M (23, 27, 28). Binding of '251-IL4 to soluble IIr4BPs in
ascites or purified preparations wasmeasured using centrifugation
through Sephadex G-50 minicolumns, in order to separate free from
bound 1211-11,4 (15) . Briefly, samples were incubated with 1211-
11,4 (at 2 x 10-1° M) for 45 min at 4°C or 37°C, loaded onto
1 ml syringes containing Sephadex G-50 and centrifuged for 60 s
at 600g. Bound 12'1-IL4 was excluded while free 1211-IL4 was re-
tained inside thecolumn . In both cellular and soluble binding assays,
specific 1211-IL4 binding was calculated by subtracting non-specific
binding (cpm bound in the presence of a 100-fold molar excess of
unlabeled IL4) from total binding (cpm bound in the absence of
unlabeled IL4) .
Kinetic Binding Studies .
￿
(A) Dissociation experiments: To study
the dissociation of bound 1211-IL4 from membrane I1ARs on
HT-2 cells or from soluble IIr4BPs, cells or purified IL4BP prepa-
rations were incubatedwith 1211-IL4 (100pM) in RPMI-1640 con-
taining 5% FCS for 60 min at 4°C or 37°C . At0time, a 100-fold
molar excess of unlabeled 11,4 (equilibrated to the same tempera-ture) was added and the mixtures were incubated at 4°C or 37°C .
At intervals thereafter, 100 wl aliquots (containing 1( 6 cells or a
constant amount ofIL4BPs) were centrifuged through a dibutyl/di-
octyl phthalate oil mixture (HT-2 cells) or Sephadex G-50 mini-
columns (soluble IL4BPs) and the remaining associated radioac-
tivity (bound "1-IL4) was measured . Dissociation rate constants
(k2) for both membrane and soluble IL4Rs were calculated using
plots of In [HR]/[HR]o versus time, where [HR]o is the concen-
tration of bound ligand at the initiation of the experiment (t =
0) and [HR] is the concentration of bound ligand at any given
time . The dissociation rate constant, (k2), is defined by the nega-
tive slope of the resulting curve, i .e., slope = -k2-
(B) Association experiments : To study the association kinetics
ofIL4 to membranebound or soluble IL4Rs, HT-2 cells or a purified
preparation of IL4BPs were resuspended in RPMI-5% FCS . At
0 time, lass-IL4 was added to a final concentration of 200 or 500
pM, for cells or purified IL4BPs, respectively. Specifically-bound
1211-114 was determined at different times after the addition of
the labeled ligand, as described above. Association rate constants
(k,) were calculated using plots of In [HR]eq/([HR]eq - [HR])
versus time, where [HR]eq is the concentration of ligand bound
at equilibrium and [HR] is the concentration of ligand bound at
any given time . The slope of the resulting curve is equal to the
sum of the dissociation rate constant (k2) and the product of the
association rate constant (k 1) and the ligand concentration, i.e .,
slope = (k2 + k1[H]) .
(C) Dissociation rate constants : Dissociation constants (Kd) based
on kinetic binding data for membrane IL4Rs on HT-2 cells and
soluble IIL4BPs were calculated as the ratio of the dissociation rate
constant to the association rate constant, i .e., Kd = k2/k1 .
Protection of 'zsl-IL4 from Proteolysis by IL4BPs.
￿
Constant
amounts of 1211-IL4 (5 x 10^ cpm) in 50 u1 of PBS containing
1 mg/ml BSA as carrier protein, were incubated at 4°C or 37°C
with 1 or 0.3 Fcg of immobilized trypsin in the presence or absence
of enough purified II,4BPs to bind >95% of the 1211-IL4 as de-
termined by the soluble binding assay. After 15 min, 50 Al of 2x
Laemmli sample buffer containing 5% 2-ME was added to each
tube and the mixtures were placed in a boiling water bath for 3
min. The extent ofproteolysis was then analyzed semi-quantitatively
by SDS-PAGE in a 15% polyacrylamide gel followed by autoradi-
ography.
Results
Purification ofIL4BPs from Murine Ascitic Fluid.
￿
IL4BPs
were purified from pooled mouse ascitic fluid by affinity chro-
matography on a rIL4-Affigel-10 column followed by removal
of contaminating proteins by hydroxyapatite chromatography.
This method resulted in a >105-fold increase in specific ac-
tivity (binding activity/protein concentration) and an approx-
imate recovery of15-20% . After SDS-PAGE, the IL4-binding
activity was associated with a relatively broad band of 30-40
kD (Fig. 1 A) . The broad bandmay be due to heterogeneity
in glycosylation or the existence of multiple forms of IL4BPs .
The IL4BPs purified by affinity chromatography were identical
to the IL4BPs prepared using a previously published protocol
(15) involving a combination of gel filtration, Blue-Sepharose
affinity chromatography, chromatofocusing and hydrophobic
chromatography. The 11,4-binding activity of such prepara-
tions could be completely removed by passage through an
IL4Affigel-10 column .
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Structural and Immunologic Similarities between sIL4R and
IL4BPs. Because IL4BPs and soluble rIIr4Rs have similar
molwt and affinities for RA, IL4BPs might be natural, soluble
forms ofIL4Rs. To investigate this possibility, one-dimensional
(Cleveland) peptide maps (25) obtained after V8 protease or
trypsin digestion of both iodinated soluble, rIL4Rs and
purified IL4BPs, were compared. As shown in Fig. 1 B, pro-
teolysis with either enzyme generated similar tyrosine-
containing peptide maps from both soluble rIL4Rs and
purified IL4BPs . Since similar peptide patterns suggest similar-
ities in the primary structure of proteins, these results indi-
cate that the IL4BPs purified from ascitic fluid are structur-
ally related to IL4Rs and suggest that IL4BPs might be the
naturally-occurring forms of soluble IL4Rs. This interpreta-
tion was supported by evidence that a monoclonal rat anti-
murine IL4R antibody, which reacts with both membrane
and soluble IL4Rs (21), but not normal rat IgG, immuno-
precipitated IL4BPs (Fig. 1 A) and completely inhibited the
IL4-binding activity ofpurified IL4BP preparations (Fig . 2) .
Inhibition ofBinding of 1251-IL4 to Cells at 4 and 37°C.
￿
In
previous experiments we observed that low concentrations
of M4BPs were very effective in blocking the binding of
1251-IL4 to T or B cells at 4° C, but that the amounts
needed to block the biological activity of 1174 on the same
cells (incubated at 37°C) were substantially higher than those
required for inhibition of binding (15) . Therefore, we deter-
mined whether the IL4BPs were equally effective at blocking
binding of 1251-IL4 to cells at 37°C . HT-2 cells (106
cells/tube) were incubated for 45 min at 4°C or 37°C with
two different amounts of 1251-IL4 (10 and 50 pM) in the
presence or absence of varying concentrations of purified IL
4BPs. The amount of cell-boundIL4 was then determined .
As shown in Fig . 3, some inhibition of binding of 1251-IL4
was observed at 37°C . However, the IL4BPs competed much
less effectively for binding of IL4 to HT-2 cells at this tem-
perature than at 4°C . The relatively poor ability of the IL
4BPs to compete for binding at the higher temperature was
not due to an effect ofreceptor internalization at 37°C, since
identical results were obtained if assays were carried out in
the presence of 10mM sodium azide and 2mM 2-deoxyglucose
in order to prevent receptor internalization . Similarly, potential
inactivation of the IL4BPs at 37°C was excluded, since we
could demonstrate binding of 1211-IL-4 by the IL4BPs at
37°C in the soluble-phase binding assay andIL4BP prepara-
tions pre-incubated at either 4°C or 37°C for 60 min were
equally effective at inhibiting binding of 125I-11A to cells
when tested at 4°C (results not shown) .
Affinity ofIL4BPsfor 11,4 at 4° and 37°C.
￿
To determine
whether the differences in the inhibitory ability of IL4BPs
at 37°C were due to a temperature-induced decrease in the
binding affinity and/or in the number of IL-4-binding sites,
we performed Scatchard analyses (29) of equilibrium binding
of 1251-IL4 to soluble IL4BPs at 4°C and 37°C. In accord
with previous findings, Scatchard analysis of the binding data
at 4°C indicated the existence of a single class ofhigh-affinity
binding sites (Kd: 6 x 10' 11 M) . Although a linear curve .
was also obtained in the Scatchard plot at 37°C, a differentFigure 1 .
￿
(A) SDS-PAGE of IIL4BPs and immunoprecipitation with
monoclonal anti-114R . antibody. II.4BPs were purified from murine as-
citic fluid by affinity chromatography on an rIIL4Affigel-10 column fol-
lowed by hydroxyapatitechromatography. The purified IIL4BPs were then
iodinated using the Iodogen method ; free 1251 was removed by passage
through a Sephadex G-25 column and an aliquot was analyzed by SDS-
PAGE (10% gel) followed by autoradiography. 1 251-labeled I1'4BPs were
incubated with either normal rat IgG or a rat anti-mouse 11,4 mAb (5
kg) followed by incubation with a mouse anti-rat K light chain antibody
(MARK.1) coupled to Sepharose beads. The beads were washed andeluted
with SDS-sample buffer. Lane 1 : IIL4BPs preparation; lane 2 : IIL4BPs plus
normal rat IgG; lane3 : IIABPs plus anti-IL4RmAb. (B) One-dimensional
(Cleveland) maps of 1251-labeled soluble rIIr4R and purified 11,4BPs.
Soluble rIIL4Rs and purified IIL4BPs were iodinated and digested for 15
min at 37°C in the presence of S. aureus V8 protease or Trypsin, as de-
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Inhibition of binding of 1251_114 to purified IL4BPs by a
monoclonal rat anti-mouse IL4R (21) . Aliquots ofa purified IIL4BPprep-
aration were preincubated for 30 min at 4°C in the absence or presence
ofincreasing amounts of a rat anti-mouse IL4RmAb (" ) or normal rat
IgG (O) . 1 251-IIr4 was then added to a final concentration of 100 pM .
After 45 mins at 4°C, specific bindingwas measured using a solublephase
binding assay as described . Results are expressed as percent of a control
containingI ,4BPs in the absenceof antibodies (control: 2,500 ± 150 cpm) .
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￿
Inhibition of binding of 1251-IL4 to HT-2 cells by IL4BPs
at 4°C and 37°C. HT 2 cells (10 6 per tube) were incubated with 1251-IL4
at either 10 pM (0, ") or 50 pM (0, A) in the presence or absence
ofincreasing concentrations (0-10 ng/ml, based on IL-4-binding activity)
of a purified IIL4BP preparation . After 45 min at 4°C (0, O) or 37°C
(" , A) the cell mixtures were centrifuged through phthalate oil in order
to remove free 1251-IL4 and specific binding was determined as described
in Materials and Methods.
slope suggested a threefold decrease in affinity (Kd : 2 x
10- '° M) . A similar intercept of the y-axis by both curves
indicated virtually identical numbers ofbinding sites, arguing
against either a potential inactivation of the IIJ4BPs or a reduc-
tion in the number ofIL-4-binding sites (Fig. 4) . The three-
fold reduction in the Kd of the IL4BPs at 37°C was com-
pletely reversible if the cells were cooled to 4°C. Indeed,
preparations that were pre-exposed at 37°C for 60 min had
scribed. Resulting peptides patterns were compared after SDS-PAGE (15%
gel) and autoradiography. Lanes 1, 3, and 5 : soluble rIL4R; lanes 2, 4,
and 6 : purified IIr4BPs ; samples in lanes 1 and 2 were undigested, samples
in lanes 3 and 4 were digested with V8 protease, and those in lanes 5 and
6 were digested with trypsin .m m
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Figure 4 .
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Scatchard analysis of binding of 1251_114 to IL4BPs at 4°C
and 37°C . Equilibrium binding of 1251-IL4 to purified IL4BPs was de-
termined in a soluble phase binding assay at both 4°C (O) and 37°C (" )
using constant amounts of IL4BPs and increasing amounts of 1251-IL4 .
Kd and Bmax values were (6 x 10-11 M ; 36.8 fmoles) and (2 x 10 - 1o
M ; or 34 .2 fmoles) at 4°C and 37°C, respectively.
Kd values at 4°C that were identical to those obtained for
preparations maintained at 4°C. These results suggested that
a potential temperature-induced change in conformation might
have altered the binding characteristics of the IL4BPs .
Kinetic Binding Studies.
￿
Although, as determined by equi-
librium binding studies (30-32), the affinities of the p75 and
p55 subunits of the IL2R differ by only 10-fold, kinetic
binding measurements for 11,2 have revealed very significant
differences in the manner in which thetwo different subunits
bind 11,2 (33, 34) . Whereas the p75 (intermediate affinity)
subunit has very slow association and dissociation rates, the
p55 (low affinity) subunit has very rapid association/dissoci-
ation rates . The high-affinity IL2R (p75/p55) combines the
fast association of p55 and the slow dissociation of p75 (33,
34) . By analogy, even though equilibrium binding analyses
indicated that the IL4BPs and membrane IL4Rs have similar
Kds, we determined whether potential differences in associa-
tion/dissociation kinetics between soluble and membrane IL
4Rs at 4°C and 37°C, might explain the relatively lower
inhibition by the IL4BPs at 37°C .
Kinetic association and dissociation rates were thus calcu-
lated for both the soluble IL4BPs (soluble-phase binding assay)
and formembrane IL4Rs (usingHT-2 cells) at both temper-
atures. As shown in Fig . 5, dissociation of 114 from either
the IL4BPs or membrane IL4Rs at 4°C was relatively slow,
with t1i2 values of -112 and -180 min, respectively . At
37°C, however, the dissociation of 114 from soluble IL4BPs
differed significantly from that ofmembrane I1,4Rs : the t1/2
for the IL4BPs was only -2 min, whereas that ofmembrane
IL4Rs was -69 min . Although association rates were rela-
tively fast for both soluble and membrane IL4Rs, rates were
faster for the IL4BPs. Association and dissociation plots (Fig.
5 e and J) were used to calculate the kinetic rate constants
for both membrane IL4Rs and soluble IL4BPs, at 4°C and
37°C . These values are summarized in Table 1 . Estimation
ofKd values based on kinetic parameters (association/dissoci-
ation) confirmed the Kd values obtained from equilibrium-
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Kinetics of IL4 binding to membrane and soluble IL4Rs .
(A and B) Association of 1251-IL4 to HT-2 cells (A) and soluble IL4BPs
(B) at 4°C (O) and 37°C (" ) . (C and D) Dissociation of 1251-IL4 from
membrane (HT-2 cells, C) or soluble (IL4BPs, D) II,4Rs at 4°C (O) and
37°C (" ) . Dissociation at 37°C was also measured in the presence of 10
mM sodium azide and 2 mM 2-deoxyglucose (A) . Specific binding for
both the cell and solublephase binding assays was calculated after subtrac-
tion ofnonspecific binding (cpm bound in the presence ofa 100-fold molar
excess of unlabeled 11,4) from the Total binding . (E and F) Natural log
plots of Association (E) and Dissociation kinetics (F) of 1251-11,4 binding
to membrane (A, A) and soluble IL4BPs (O, " ) at 4°C (A, O) and
37°C (A, " ) . Kinetic rate constants were calculated based on these plots
as described under Materials and Methods.
binding studies for both soluble and membrane IL4Rs.
Moreover, Kd values for soluble IL4BPs obtained from ki-
netic data, showed a six-eight-fold higher dissociation con-
stant at 37°C, reflecting the significantly faster dissociation
rate ofIL4BPs at this temperature. Thus, the faster dissocia-
tion rate and lower affinity of soluble IL4BPs at 37°C or
4°C might explain the differences in inhibition of binding
at the two different temperatures .
Two-step Incubation of 1251--IL4 with IL4BPs and HT-2
Cells. The different kinetic binding properties ofsoluble IL
4BPs and membrane IL4Rs at 37°C have important impli-
cations for the potential physiological role of soluble IL4BPs
in vivo. Because of the fast association/dissociation rates of
114 from soluble IL4BPs at 37°C, IL4/IL4BP complexes
in vivo must be constantly dissociating and re-forming. In
other words they would be transient and reversible, thereby
allowing the ligand (IL4) to dissociate from one soluble IL
4BP molecule, and become available for binding to another
IL4BP molecule or alternatively, to a membrane114R. The
slower dissociation kinetics ofmembrane IL4Rs, combinedTable 1.
￿
Summary of Equilibrium and Kinetic Binding Constants for Membrane and Soluble IL-4Rs at 4° and 37°C
" Calculated from data shown on Fig . 3 .
t Calculated from data shown on Fig . 5 .
s HT-2 cells .
II Purified IL-4BP preparation .
with receptor internalization, wouldmakeIL4boundtomem-
brane IL4Rs less likely to dissociate . It should be stressed,
however, that the equilibrium of this reaction would be de-
pendent on the relative concentrations of membrane and
soluble receptors and that at high enough concentrations of
soluble receptors, effective inhibition of IL4-binding to mem-
brane IL4Rs would occur .
To test this model, we incubated a constant amount of
1251-IL4 with an excess of IL4BPs (2.5 and 7.5-times the
amount of IL4BPs required to saturate the IL4) at 4°C or
37°C . Based on the soluble-phase binding assay, it was de-
termined that all the 1251-IL4 was bound to the IL4BPs at
either temperature. The mixture was then incubated with
HT-2 cells and cell-bound 1251-IL4 was determined after 45
min at 4°C or 37°C. As shown in Fig . 6, when IL4 was
exposed to IL4BPs and then incubated with cells at 4°C,
v
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Figure 6.
￿
11,4 bound to IL4BPs remains available for binding to HT-2
cells at 37°C but not at 4°C . 1251-IL-4 (100 pm) was incubated in the
absence or presence of a 2.5- or a7.5-fold molar excess of purified IL4BPs
for 45 min at 4°C or 37°C. It was then determined, based on the soluble
phase binding assay, that >99% of the radioactivity was associated with
the IL4BPs . HT-2 cells (106/tube) were then added to the mixtures. The
incubations were continued for 45 min at 4°C or 37°C . The amount of
radioactivity associated with the cells (specific IL4-binding) was then de-
termined as described in Materials and Methods .
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greater than 90% of the IL4 remained associated with the
soluble receptors and was unable to bind to membrane IL
4Rs. In contrast, although some inhibition was observed at
37°C (20-35%), there was still significant binding of
1251-IL4 to the cells, even when all the IL4 was associated
with IL4BPs before the addition of the cells. The binding
of IL4 to HT -2 cells was completely inhibited at both tem-
peratures by the anti-IL4 mAb, 11B11 (whose binding to
IL4 is also inhibited by IL4BPs) (datanot shown), suggesting
that in order for IL4 to bind to membrane IL4Rs on the
HT-2 cells, it must first dissociate from the IL4BPs (only
free IL4 can bind to 11B11 antibodies) .
Protection ofH,4from Proteolysis by IL4BPs.
￿
The fact that
IL4 is able to rapidlybind to and dissociate from theIL4BPs
at 37°C, thus becoming available to bind to membrane IL
4Rs, raises the possibility that IL4 mightuseIL4BPs as "carrier
Figure 7.
￿
Protection of 11,4 from proteolytic degradation . 1251-IL4 was
incubated with Trypsin at 1 or 0.3 gg/tube in the presence (lanes 2, 4,
6, 8, 10, and 12) or absence (lanes 1, 3, 5, 7, 9, and 11) of a two-fold
molar excess of purified IIr4BPs in 50 p.l of PBS containing 1 mg/mlBSA.
After 15 min at 37°C, 21°C or 4°C, 50 Ftl of SDS-PAGE sample buffer
was addedand the mixtures were incubated for 3 min in a boiling water
bath . Digestion of the samples was estimatedby analysis usingSDS-PAGE
(15% gel) and autoradiography. Lanes 1 and 2: undigested; lanes 3-6,
digested with 1 gg (3-4) or 0.3 hg trypsin (5 and 6) at 37°C; lanes 7,
8 digested with 1 P,g trypsin at 4°C; and lanes 9-12, digested with 1 Fig
(9 and 10) or 0.3 Wg trypsin (11 and 12) at 21°C .
IL-4
Receptor Temperature
°C
Equilibrium
dissociation
constant (Kd)"
x 10- " M
tV2
min
Kinetic binding
Dissociation (k2)
min- '
constantst
Association (k2)
Mol- ' - min'
k2/k,
x 10-" M
Membranes 4 4 180 3.85 x 10- ' 2.57 x 108 1 .5
37 7 69 1.01 x 10 -2 2.34 x 108 4.3
Solublell 4 6 112 6 .21 x 10 - ' 3.87 x 108 1 .6
37 20 2 .3 3 .07 x 10- ' 2.34 x 109 13.0proteins" in vivo . In view of reports suggesting that a-2-
macroglobulin acts as a carrier protein for IIr6 in the circula-
tion and that it protects IIr6 from proteolytic degradation
(35), we determined whether the binding of ILA to soluble
IL4BPs would confer protection against proteolytic degra-
dation . Constant amounts of 1151-IL4 were preincubated in
the presence or absence of a saturating amount of IL4BPs
in a solution containingBSA as a carrier protein . Two different
concentrations of immobilized trypsin were then added and
the mixtures were incubated at 4°C, 21°C or 37°C . The
extent of proteolysis of 1251-IL4 was then ascertained by
SDS-PAGE and autoradiography. As shown in Fig . 7, incu-
bation of IL-4 with IL4BPs in BSA and in the absence of
trypsin did not result in degradation or alteration of the mo-
bility of IL4 . When trypsin was added, the IL4BPs partially
protected IL-4 from proteolytic degradation at all tempera-
tures tested, although this effect was more pronounced at
4°C than at 37°C . This might reflect the faster dissociation
of IL4 from the IL4BPs at higher temperatures, allowing
more 11,4 to be exposed to the protease. Nonetheless, even
at 37°C there was a significative difference in the extent of
degradation of IL4 in the presence or absence ofthe IL4BPs.
The decreased degradation of IL-4 in the presence of the IL
4BPs was due to a decreased susceptibility of IL4/IL4BPs
complexes to enzymatic attack and not to an inhibitory effect
on trypsin itself, since the hydrolysis of a chromogenic sub-
strate for trypsin (N-benzoyl-Larginine ethyl ester) was
unaffected by the addition of IL4BPs (data not shown) .
Discussion
Three major findings have emerged from these studies : (a)
soluble IL4BPs in mouse sera and ascites are structurally and
antigenically similar to soluble rIL4Rs; (b) the binding prop-
erties of the IL4BPs/sIL4Rs are consistent with a potential
role as carrier proteins for IL-4 in vivo . In this regard, the
dissociation of IL-4 from sIL4Rs is rapid, whereas dissocia-
tion of IL-4 from membrane IL4Rs is slow, suggesting that,
at 37°C, IL-4 is not effectively sequestered from membrane
IL4Rs even when bound to soluble IL4Rs (at the concen-
trations normally present in serum) ; (c) 114 is partially pro-
tected from enzymatic degradation following its binding to
soluble IL4BPs.
Several lines of evidence suggest that the IL4BPs present
in murine ascites are naturally-occurring forms of soluble IL
4Rs . Hence, Mosley, et al . (9) have reported that cDNAs
encoding truncated, soluble forms of the murine IL4Rs (sIL
4R) are expressed in several types ofmurine cells and Fanslow,
et al . (36) have recently reported the presence of molecules
in mouse serum and ascitic fluid that react with monoclonal
anti-IL-4R antibodies . Since the IL4BPs and sIL4Rs have
similar binding affinities for IL-4 (Kds : N5 x 10 -11 M) (9,
15), similar molecular weights (9, 15), and can competitively
inhibit the binding and the biologic activity of 114 (9, 15,
22), the IL4BPs are most likely natural forms of soluble IL
4Rs. The present data support this contention basedon similar
peptide maps generated after proteolytic digestion as well as
antigenic cross-reactivity. Whether or not the soluble IL
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4BPs originate from an alternatively-splicedmRNA encoding
soluble IIr4Rs, or from proteolytic cleavage of membrane
IL4Rs remains to be determined. Indeed, both mechanisms
might contribute to the presence of IL4BPs in biological fluids.
Based on the fact that the cDNA clones that encode soluble
IIr4Rs contain a 114 by insertion that results in the addition
ofsixnew amino acid residues at the C-terminus (9), it should
be possible to distinguish soluble IL-4R molecules generated
by alternative mRNA splicing from those shed as a result
of proteolytic cleavage by comparison of their C-terminal
amino acid sequences . Regardless ofthe mechanism involved
in their generation, it will be important to determine what
cell types release sIL4Rs, the signals involved in this process
and the factors regulating their generation.
An obvious question regarding the presence of soluble IL
4Rs in biological fluids is whether they are involved in the
regulation of IL4 activity in vivo. Based on evidence indi-
cating that either purified IL4BPs or soluble rIIr4Rs inter-
fere with the binding and activity of 114, we initially sug-
gested that soluble IL4Rs might act in vivo by competing
with cellular IL4Rs for the binding of free IL-4 in the circu-
lation (15) . Unexpectedly, results of the present studies indi-
cate that IL4BPs, at concentrations normally found in serum,
(-20 ng/ml based on IL-4 binding activity) are not very effec-
tive competitors ofmembrane IL4Rs at physiological tem-
peratures and that their properties are more consistent with
a potential role as "carrier proteins" for IL-4 in vivo.
A comparison of the kinetics of IL4-binding to soluble
and membraneIL4Rs at 4°C and 37°C, disclosed an impor-
tant difference between both IL4Rs forms . Thus, dissocia-
tion of IL-4 from soluble and membrane IL4Rs was relatively
slow at 4°C, whereas dissociation of IL-4 from soluble IL
4BPs followed significantly faster kinetics than that from mem-
brane IL4Rs at 37°C. Since dissociation of 1251-IL4 was
measured after the addition of a 100-fold excess of unlabeled
IL4, the possibility existed that the apparent increase in dis-
sociation rate could be accounted for by negative-cooperativity'
among soluble IL4Rs at 37°C . However, the fact that
Scatchard curves for the binding of 1251-IL4 to sIL4Rs at
37°C were not curvilinear argues against this possibility.
The molecular mechanisms responsible for the difference
between the dissociation rates of soluble and membrane IL
4Rs are not clear. It is possible that increased temperature
and/or ligand binding induce conformational changes in the
soluble IL4BPs that result in the accelerated dissociation rate .
These changes may not be induced in the membrane IL4Rs
because of stability conferred by anchoring in the membrane
through transmembrane and intracytoplasmic domains and/or
association with other membrane protein(s) .
Because of the fast dissociation rate at 37°C, IL4 mole-
cules would be constantly associating and dissociating from
sIL4R molecules, thereby increasing their chance ofbinding
to membrane IL4Rs . However, the equilibrium of 11,4 be-
tween both receptor forms would remain dependent upon
the relative concentrations of soluble vs. membrane IL4Rs
at any given anatomical site. Since 114 bound to soluble IL
4BPs can dissociate and bind to membrane IL4Rs, this sug-
gests that even though most of the IL-4 in the circulationmight bebound to soluble IL4BPs, it would still be available
for binding to membrane IL4Rs, especially at those anatom-
ical sites with high concentrations of IL-4R' cells (i.e., in-
creased ratio ofmembrane IL4Rs to sIL4Rs) . In the circula-
tion or in nonlymphoid tissues, the lower ratio ofmembrane
to soluble IIT4Rs would favor binding to solubleIL4Rs . This
could be a mechanism whereby active IL4 is preferentially
delivered to lymphoid organs such as lymph nodes, spleen,
thymus, etc ., while preventing its binding to cells at other
sites. In addition, activated cells in distal sites expressing high
densities ofIL4Rswould have an advantage in capturing cir-
culating IL4 carried by soluble IL4Rs . Such cells could thereby
utilize the 11,4 produced at distant sites . Consistent with this
possibility is the observation that the binding of IL4 by IL
4BPs protects IL-4 from proteolytic inactivation ; it might also
prolong the half-life of IL4 in the circulation by preventing
its clearance . These possibilities could provide a mechanism
for amplifying an immune response.
One implication of the above model is that pathological
conditions that result in alterations in the normal levels of
soluble IL4Rs, might lead to overall increased or decreased
IL4 activity by altering the sIL4Rs/mIL4Rs ratio. Hence,
it will be important to correlate the changes in the serum
levels of soluble IL4Rs with the changes in the immune system
observed in a variety ofinfectious diseases, immunodeficiencies,
autoimmune and malignant diseases .
In addition to the potential role for soluble IL4Rs in the
regulation of11,4 activity under normal and pathological con-
ditions, soluble IL4Rs and other soluble cytokine receptors,
are also very attractive candidates for immunotherapy (37) .
In this regard, recombinant soluble IL4Rs (if given in
sufficiently high pharmacological concentrations) could be
employed to selectively block IL-4 activity in vivo. This could
be important in the treatment of allergic conditions. Therapy
with soluble rIL4Rs would have some important advantages
over immunotherapy with agents such as anti-cytokine or
anti-cytokine receptor antibodies . Thus, the elicitation of an
antibody response against the soluble IL4Rs would be un-
likely. In addition, their smaller size might facilitate extrava-
sation and/or penetration of tissues.
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